Direkt zum Inhalt
Merck
  • Morphine and oxycodone, but not fentanyl, exhibit antinociceptive effects mediated by G-protein inwardly rectifying potassium (GIRK) channels in an oxaliplatin-induced neuropathy rat model.

Morphine and oxycodone, but not fentanyl, exhibit antinociceptive effects mediated by G-protein inwardly rectifying potassium (GIRK) channels in an oxaliplatin-induced neuropathy rat model.

Neuroscience letters (2014-08-17)
Tomoe Kanbara, Atsushi Nakamura, Masahiro Shibasaki, Tomohisa Mori, Tsutomu Suzuki, Gaku Sakaguchi, Toshiyuki Kanemasa
ZUSAMMENFASSUNG

It has begun to be understood that μ-opioid receptor (MOR) produces ligand-biased agonism, which contributes to differential physiological functions of MOR agonists. We previously demonstrated that in oxaliplatin-induced neuropathy in rats, morphine and oxycodone exhibited antinociceptive effects while antinociception of fentanyl was partial, and such different efficacies might result from the different level of Gi/o protein activation. Based on our background, to reveal further mechanism, we focused on the role of Gi/o protein-related downstream signaling, the G-protein inwardly rectifying K(+)1 (GIRK1) channel. The GIRK1 channel blocker tertiapin-Q (30pmol) was intracerebroventricularly (i.c.v.) or intrathecally (i.t.) administered to rats with oxaliplatin-induced neuropathy. The antinociception of systemic morphine (3mg/kg, subcutaneously (s.c.)) was suppressed only by pretreatment of i.t. tertiapin-Q, while supraspinal tertiapin-Q suppressed only the antinociception of systemic oxycodone (0.56mg/kg, s.c.). Partial antinocicpetion of fentanyl (0.017mg/kg, s.c.) was neither affected by i.c.v nor i.t. tertiapin-Q. These results demonstrated that GIRK1 channels differentially contribute to antinociceptive effects of MOR agonists, and that action site of GIRK1 channels is also different between morphine and oxycodone in oxaliplatin model. This study suggests the possibility that GIRK1 channels have a crucial role for antinociception of MOR agonists in oxaliplatin-induced neuropathy.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
D-(+)-Glukose -Lösung, 45% in H2O, sterile-filtered, BioXtra, suitable for cell culture
Sigma-Aldrich
D-(+)-Glukose -Lösung, 100 g/L in H2O, sterile-filtered, BioXtra, suitable for cell culture
Sigma-Aldrich
α-D-Glucose, anhydrous, 96%
Sigma-Aldrich
Glucose -Lösung, BioUltra, for molecular biology, ~20% in H2O
Sigma-Aldrich
Oxaliplatin, powder
Supelco
Oxaliplatin, Pharmaceutical Secondary Standard; Certified Reference Material
Oxaliplatin, European Pharmacopoeia (EP) Reference Standard
Supelco
Oxycodon -hydrochlorid, analytical standard
USP
Oxaliplatin, United States Pharmacopeia (USP) Reference Standard
Supelco
D-(+)-Glukose -Lösung, 1 mg/mL in 0.1% benzoic acid, standard for enzymatic assay kits GAGO20, GAHK20, STA20, analytical standard